Medicus Pharma (MDCX) announces that its Investigational New Animal Drug, INAD, has received Minor Use in Major Species Designation, MUMS, from the U.S. Food and Drug Administration, FDA, for its dissolvable Doxorubin-containing microneedle array, D-MNA, to treat external squamous cell carcinoma, SCC, in horses. The company received a notification from the FDA on December 9th 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX: